Search results for "Castration"

showing 10 items of 50 documents

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

2016

<b><i>Purpose:</i></b> The present study aims to evaluate the efficacy of cabazitaxel in combination with prednisone treatment in Italian patients affected by hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel plus prednisone. <b><i>Methods:</i></b> Thirty patients with mCRPC were enrolled between June 2013 and January 2016 (the last follow-up was in January 2016). Cabazitaxel was used according to the summary of product characteristics and administered at a dose of 25 mg/m<sup>2</sup> every 3 weeks plus oral prednisone at a dose of 5-mg tablets twice a day continuously. The…

OncologyMalemedicine.medical_specialtyCancer Research030232 urology & nephrologyProstate neoplasmAntineoplastic AgentsDocetaxelCastration resistantAdenocarcinomaTaxaneSingle CenterAntineoplastic Agent03 medical and health sciencesProstate cancer0302 clinical medicinePrednisoneInternal medicineTaxoidmedicineClinical endpointHumansProspective StudiesAgedResponse rate (survey)GynecologyCabazitaxelbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseMetastatic castration-resistant prostate cancerProspective StudieProstatic Neoplasms Castration-ResistantDocetaxelOncologyCabazitaxel030220 oncology & carcinogenesisChemotherapy regimenDisease ProgressionPrednisoneTaxoidsbusinessmedicine.drugHuman
researchProduct

Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain

2019

Abstract Introduction The objective of the study was to determine the factors independently related with the development of castration resistance (CR) in prostate cancer (PC) in the medium term. Material and methods 155 patients diagnosed with metastatic PC with a follow-up of up to 39 months. Data taken from the National PC Registry. The evaluated variables were age, PSA, nadir PSA, Gleason, perineural invasion, TNM stages, and ADT type (intermittent / continuous). Results Mean follow-up 26,2 ± 13,4 months. 47.1% developed early CR, with mean time until onset of 12,2 ± 8,7 months. Univariate analysis: the mean PSA was correlated with CR (290 ± 905,1 ng/mL in non CR, 519,1 ± 1437,2 ng/mL in…

Oncologymedicine.medical_specialtyUnivariate analysisMultivariate analysisbusiness.industry030232 urology & nephrologyPerineural invasionGeneral Medicinemedicine.diseaseLower risk03 medical and health sciencesProstate cancer0302 clinical medicineCastration ResistanceInternal medicineTumor stagemedicinebusinessNadir (topography)Actas Urológicas Españolas (English Edition)
researchProduct

The maternal hormone in the male brain: Sexually dimorphic distribution of prolactin signalling in the mouse brain.

2018

Research of the central actions of prolactin is highly focused on females, but this hormone has also documented roles in male physiology and behaviour. Here, we provide the first description of the pattern of prolactin-derived signalling in the male mouse brain, employing the immunostaining of phosphorylated signal transducer and activator of transcription 5 (pSTAT5) after exogenous prolactin administration. Next, we explore possible sexually dimorphic differences by comparing pSTAT5 immunoreactivity in prolactin-supplemented males and females. We also assess the role of testosterone in the regulation of central prolactin signalling in males by comparing intact with castrated prolactin-supp…

0301 basic medicineMaleCell signalingPeptide HormonesSignal transductionBiochemistrychemistry.chemical_compoundMice0302 clinical medicineArcuate NucleusSTAT5 Transcription FactorMedicine and Health SciencesMorphogenesisTestosteroneLipid HormonesPhosphorylationTestosteroneNeuronsSex CharacteristicsMultidisciplinarySexual DifferentiationCerebrumReproductionQRBrainHormones esteroidesSTAT signalingmedicine.anatomical_structureCervell Localització de funcionsHypothalamusAndrogensMedicineFemaleAnatomyhormones hormone substitutes and hormone antagonistsResearch Articlemedicine.medical_specialtyendocrine systemCell biologyScienceHypothalamusBiologyResearch and Analysis MethodsAmygdala03 medical and health sciencesInternal medicinemedicineAnimalsCastrationImmunohistochemistry TechniquesSexual DimorphismProlactin receptorBiology and Life SciencesProlactinHormonesProlactinSexual dimorphismHistochemistry and Cytochemistry Techniques030104 developmental biologyEndocrinologyCastrationchemistryImmunologic Techniques030217 neurology & neurosurgeryHormoneDevelopmental BiologyPloS one
researchProduct

Effect of starvation on parasite-induced mortality in a freshwater snail (Potamopyrgus antipodarum).

1999

The level of host exploitation is expected, under theory, to be selected to maximise (subject to constraints) the lifetime reproductive success of the parasite. Here we studied the effect of two castrating trematode species on their intermediate snail host, Potamopyrgus antipodarum. One of the trematode species, Microphallus sp., encysts in the snail host and the encysted larvae “hatch” following ingestion of infected snails by birds. The other species, Notocotylus gippyensis, by contrast, releases swimming larvae; ingestion of the snail host is not required for, and does not aid, transmission to the final host. We isolated field-collected snails for 3 months in the laboratory, and followed…

biologyEcologyPotamopyrgusfungiZoologyParasitismSnailbiology.organism_classificationParasitic castrationFreshwater snailbiology.animalparasitic diseasesMicrophallusTrematodaEcology Evolution Behavior and SystematicsPotamopyrgus antipodarumOecologia
researchProduct

Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer

2017

Background: Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications. In this context, the positron emitter scandium-44 is an attractive alternative for PET imaging. We report the synthesis of [44Sc…

OncologyMalemedicine.medical_specialtytheranostics.Medicine (miscellaneous)Context (language use)SpleenGallium RadioisotopesLutetiumurologic and male genital diseases030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancerHeterocyclic Compounds 1-Ring0302 clinical medicineInternal medicinePositron Emission Tomography Computed TomographyLNCaPmedicineDosimetryHumansRadiometryPharmacology Toxicology and Pharmaceutics (miscellaneous)AgedRadioisotopesUrinary bladderChemistrybusiness.industryDipeptidesProstate-Specific Antigenmedicine.diseaseprostate cancerPSMA-617scandium-44Small intestineProstatic Neoplasms Castration-Resistantmedicine.anatomical_structurePET030220 oncology & carcinogenesisAbsorbed doseRadiopharmaceuticalsNuclear medicinebusinessScandiumResearch PaperHalf-LifeTheranostics
researchProduct

Effect of prolactin and the anti-prolactin bromocriptin on the testosterone uptake and metabolism in androgen-sensitive and insensitive canine organs

1976

Prolactin promotes the growth and function of the prostate in low doses, whereas high doses or previous castration reduce this effect. The antiprolactin bromocriptin should reverse the prolactin action. In the castrated dog the highest accumulation of H3-testosterone given i.v. occurred in the prostate as compared with muscle, urethra, penis, liver and kidney. Prolactin pretreatment increased the radiosteroid uptake only in the liver. Converseley, bromocriptin suppressed the tracer incorporation into the liver, but increased prostatic accumulation. The highest testerone reduction occurred in the prostate of the untreated castrated dogs as compared with other organs. Prolactin suppressed 5 a…

Malemedicine.medical_specialtymedicine.drug_classUrologyKidneychemistry.chemical_compoundDogsUrethraProstateInternal medicinemedicineAnimalsTestosteroneCastrationErgolinesBromocriptineTestosteroneMusclesProstateMetabolismAndrogenProlactinProlactinCastrationmedicine.anatomical_structureEndocrinologyLiverchemistryDihydrotestosteronePenisPenismedicine.drugUrological Research
researchProduct

Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences

2012

With a novel antibody against the rat Na+-d-glucose cotransporter SGLT2 (rSGLT2-Ab), which does not cross-react with rSGLT1 or rSGLT3, the ∼75-kDa rSGLT2 protein was localized to the brush-border membrane (BBM) of the renal proximal tubule S1 and S2 segments (S1 > S2) with female-dominant expression in adult rats, whereas rSglt2 mRNA expression was similar in both sexes. Castration of adult males increased the abundance of rSGLT2 protein; this increase was further enhanced by estradiol and prevented by testosterone treatment. In the renal BBM vesicles, the rSGLT1-independent uptake of [14C]-α-methyl-d-glucopyranoside was similar in females and males, suggesting functional contribution of…

Malemedicine.medical_specialtyPhysiologyImmunocytochemistryCarbohydrate metabolismBiologyKidneyMicechemistry.chemical_compoundimmunocytochemistry; mRNA expression; Na+-D-glucose cotransport;Sex FactorsSodium-Glucose Transporter 2D-GlucoseInternal medicinemedicineAnimalsTestosteroneCastrationRNA MessengerRats WistarKidneyMembrane Transporters Ion Channels and PumpsEstradiolMicrovilliSymportersGalactoseKidney metabolismCell BiologyRatsMice Inbred C57BLGlucosemedicine.anatomical_structureEndocrinologychemistryGalactoseSymporterFemaleCotransporterAmerican Journal of Physiology-Cell Physiology
researchProduct

Inhibition of Platelet Aggregation Caused by Estrogen Treatment in Patients with Carcinoma of the Prostate

1975

Platelet aggregation is increased in patients with carcinoma of the prostate treated with estrogens. Hence, these patients have a high incidence of cardiovascular and thromboembolic diseases. Platelet aggregation has been tested with the platelet aggregation test. It was inhibited by administration of 500 mg. acetylsalicylic acid twice daily. An aggregation inhibiting effect has been found in all 38 patients. To reduce the excess hazards of cardiovascular complications of estrogens in treating carcinoma of the prostate acetylsalicylic acid is recommended as an adjunct therapy.Estrogen therapy for prostatic carcinoma may lead to the development of cardiovascular complications, such as thromb…

Malemedicine.medical_specialtyPlatelet Aggregationmedicine.drug_classUrologyPopulationPharmacologyPlatelet AdhesivenessProstateInternal medicineCarcinomaHumansEndocrine systemMedicineCastrationeducationDiethylstilbestroleducation.field_of_studyAspirinEstradiolbusiness.industryGenitourinary systemProstatic NeoplasmsCancerEstrogensmedicine.diseaseEndocrinologymedicine.anatomical_structureEstrogenbusinessHormoneJournal of Urology
researchProduct

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Pro…

2017

Abstract Background The androgen receptor splice variant 7 (AR-V7) is associated with resistance to hormonal therapy in castration-resistant prostate cancer (CRPC). Due to limitations of the methods available for AR-V7 analysis, the identification of a reliable detection method may facilitate the use of this biomarker in clinical practice. Objective To confirm AR-V7 as a predictor of resistance to hormonal therapy and develop a new approach to assess AR-V7 by highly sensitive digital droplet polymerase chain reaction (ddPCR) in plasma-derived exosomal RNA. Design, setting, and participants Plasma samples were collected from 36 CRPC patients before they began second-line hormonal treatment. …

Oncology0301 basic medicineMaleResistanceExosomeschemistry.chemical_compoundProstate cancer0302 clinical medicineProtein IsoformsNeoplasm MetastasisReceptorAged 80 and overProstate cancerMiddle AgedProstatic Neoplasms Castration-ResistantReceptors Androgen030220 oncology & carcinogenesisBenzamidesAdenocarcinomaBiomarker (medicine)Hormonal therapyAR-V7; Digital droplet PCR; Exosomes; Hormonal therapy; Pharmacogenetics; Prostate cancer; Resistance; UrologyAndrostenesHormonal therapymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classUrologyCastration resistantAdenocarcinomaDisease-Free Survival03 medical and health sciencesSDG 3 - Good Health and Well-beingInternal medicineNitrilesPhenylthiohydantoinmedicineEnzalutamideHumansAgedDigital droplet PCRPlasma derivedbusiness.industryRNAAndrogen Receptor Splice Variant 7medicine.diseaseAndrogenEndocrinology030104 developmental biologychemistryPharmacogeneticsDrug Resistance NeoplasmCancer cellCancer researchRNAAR-V7businessPharmacogenetics
researchProduct

The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.

2017

<b><i>Background/Aim:</i></b> Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. <b><i>Subjects and Methods:</i></b> In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated. <b><i>Results:</i></b> Radium-223 was well tolerated, with a m…

0301 basic medicineOncologyDrugRadium-223MaleCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAntineoplastic AgentsBone NeoplasmsDocetaxel03 medical and health sciencesProstate cancer0302 clinical medicineQuality of lifeInternal medicinemedicineHumansmedia_commonAgedRetrospective StudiesAged 80 and overRadioisotopesbusiness.industryBone metastasisRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseProstatic Neoplasms Castration-Resistant030104 developmental biologyOncologyDocetaxelItaly030220 oncology & carcinogenesisQuality of LifeAlkaline phosphatasePrednisoneTaxoidsRadium-223 Bone metastasis Prostate cancer Radiopharmaceuticals Metastatic castration-resistant prostate cancer Quality of Lifebusinessmedicine.drugRadiumOncology
researchProduct